Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Prothena Biosciences Limited has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and the assigned art units. ESSEX, LAURA ANN is the busiest examiner for the portfolio, currently managing 1 pending office action.
The presence of the pending office actions across the assigned examiners and art units suggests a diversified prosecution profile within the Biotechnology & Pharmaceuticals field. Each pending matter is handled by a different examiner in a different art unit, requiring separate strategies for each. ESSEX, LAURA ANN handles 1 pending office action, representing a significant portion of the current pending workload. Practitioners should account for the unique procedural environment of each of the distinct art units. This structure means that the company's success is not tied to a single examiner or art unit's performance. Instead, the portfolio's progress depends on navigating separate examination paths simultaneously. The alignment of these figures indicates a broad technical reach within the sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESSEX, LAURA ANN | 1 | 60.5% | +35.2% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245533 | ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES | HOWARD, ZACHARY C | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245533 | ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES | HOWARD, ZACHARY C | 6d |
| 18456932 | METHODS OF USING ANTIBODIES RECOGNIZING TAU | ESSEX, LAURA ANN | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18456932 | METHODS OF USING ANTIBODIES RECOGNIZING TAU | ESSEX, LAURA ANN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Aug 28, 2023 |
| 18245533 | ALPHA-SYNUCLEIN VACCINE FOR THE TREATMENT OF SYNUCLEINOPATHIES | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 6d | Pending | Mar 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial